Takeda Pharmaceutical Co. Ltd.

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Takeda Pharmaceutical Co. Ltd. reported 8 stock positions worth $16.4 million. Its top holding was Ovid Therapeutics (OVID) at 59.8% of the portfolio, followed by Equillium (EQ, 15.9%) and Xilio Therapeutics (XLO, 7.6%). Compared with Q2 2025, it sold out of 3 and added to 1. The biggest buy was Lyell Immunopharma (LYEL, shares +33%) and the biggest sale an exit from Hillevax (HLVX).

Most Recent 13F
Q3 2025
Location
Tokyo, M0
CIK
0001395064
Portfolio Value
$16.4M (Q3 2025)
SEC Filing
0001395064-25-000157 ↗ filed Nov 13, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $289.0M Q1 2024 Q2 2024: $232.3M Q2 2024 Q3 2024: $38.0M Q3 2024 Q4 2024: $26.6M Q4 2024 Q1 2025: $16.2M Q1 2025 Q2 2025: $19.6M Q2 2025 Q3 2025: $16.4M $16.4M Q3 2025

Holdings 8 stocks · $16.4M
OVID Ovid Therapeutics Inc. 59.82% 7,531,996 $9.8M No change
EQ Equillium Inc. 15.94% 1,824,977 $2.6M No change
XLO Xilio Therapeutics Inc. 7.59% 1,475,121 $1.2M No change
STTK Shattuck Labs Inc. 7.53% 515,619 $1.2M No change
LYEL Lyell Immunopharma Inc. 5.45% 54,887 $891K Add +33.3%
AMWL American Well Corp. Class A 2.92% 77,733 $478K No change
RANI Rani Therapeutics Holdings Class A 0.62% 203,190 $102K No change
LAB Standard Biotools Inc. 0.13% 16,515 $21K No change

Portfolio Sells Q2 2025 → Q3 2025
HLVX Hillevax Inc. Sold out 0.00% −68.43
TSBX Turnstone Biologics Corp. Sold out 0.00% −1.64
THRD Third Harmonic Bio Inc. Sold out 0.00% −1.02

Portfolio Buys Q2 2025 → Q3 2025
LYEL Lyell Immunopharma Inc. Add +33.3% 5.45% +3.58

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 8$16.4MOVID, EQ, XLO, STTK, LYEL
Q2 2025 11$19.6MHLVX, OVID, XLO, AMWL, EQ
Q1 2025 11$16.2MHLVX, OVID, XLO, EQ, AMWL
Q4 2024 11$26.6MHLVX, OVID, XLO, EQ, STTK
Q3 2024 10$38.0MHLVX, WVE, OVID, STTK, EQ
Q2 2024 13$232.3MDNLI, HLVX, PHAT, WVE, OVID
Q1 2024 15$289.0MHLVX, DNLI, PHAT, OVID, STTK